<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212185</url>
  </required_header>
  <id_info>
    <org_study_id>09-0172</org_study_id>
    <nct_id>NCT01212185</nct_id>
  </id_info>
  <brief_title>Oxytocin Treatment of Alcohol Withdrawal</brief_title>
  <official_title>Oxytocin Treatment of Alcohol Withdrawal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, is effective
      in decreasing alcohol withdrawal symptoms, the number of bouts of withdrawal requiring
      standard medication treatment (lorazepam) and the amount of lorazepam required to control
      withdrawal bouts in individuals undergoing medical detoxification. Also, determine rates of
      subject recruitment and retention in the inpatient setting.

      Participants: 80 alcohol dependent patients, 18-65 years of age, admitted for medical
      detoxification.

      Procedures (methods): Subjects will be inpatients undergoing medical detoxification from
      alcohol. Oxytocin or placebo will be administered in a nasal spray twice daily in a
      randomized, double blind manner for three days. Withdrawal symptoms will be measured
      routinely at q4 hours and prn for length of hospital stay. Lorazepam will be given whenever
      withdrawal symptoms increase above specific parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This will be a double-blind, placebo controlled comparison of the efficacy of
      twice daily intranasal administration of oxytocin and placebo (saline) in reducing alcohol
      withdrawal symptoms, the number of bouts of withdrawal during which symptoms are of
      sufficient magnitude requiring prn lorazepam treatment (see definitions below) and the amount
      of lorazepam required to resolve withdrawal bouts. Treatment group assignment will be random
      within each sex. Subjects will be patients admitted to (University of North Carolina (UNC)
      Hospitals or the Dix Clinical Research Unit (CRU) for medical detoxification. Each treatment
      group will be composed of up to 40 subjects. Dr. Hamer, the study statistician, will
      construct a randomization plan to randomize 80 subjects to 2 groups of 40 subjects each with
      a blocksize of 4. This will be a permuted blocksize as this is a blind study.

      Procedures: Most patients who are admitted to the UNC Neuroscience Hospital Crisis
      Stabilization Unit, UNC Hospitals Family Practice or Hospitalist Services, or the Dix CRU for
      medical detoxification from alcohol will come in through the UNC Hospitals Emergency
      Department or Dorothea Dix Screening and Admissions during the late evening or early morning.
      Physical examination, medical and psychiatric history and lab tests (including complete blood
      count [CBC], magnesium, sodium, potassium, [blood urea nitrogen] BUN, creatinine, glucose,
      albumin, liver functions tests [ALT, AST, LDH, GGT], throid-stimulating hormone (TSH), B12,
      folate, urinalysis, urine toxicology screen and pregnancy test) are routinely obtained by the
      emergency department (ED)/ Dorothea Dix Screening and Admissions and/or inpatient unit during
      the admission process. Possibly in the UNC Hospitals ED/ Dorothea Dix Screening and
      Admissions and definitely after admission to these units, patients will have their vital
      signs (VSs) measured and their withdrawal symptoms quantified using the revised Clinical
      Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar scale, Sullivan et al 1989) on the
      schedule in the standard alcohol detoxification order set in the UNC Hospital electronic
      medical records system (CPOE) system. The CRU at Dorothea Dix will use a hard copy version of
      the CIWA used in the CPOE at UNC Hospitals.

      After consent is obtained, subjects will be randomly assigned to a treatment group (oxytocin
      or placebo). Prior to receiving their first intranasal treatment, an ECG will be obtained and
      blood drawn to obtain serum for assay of cytokine and allopregnanolone concentrations.
      Subjects also will rate their symptoms using the Alcohol Withdrawal Symptom Checklist (AWSC,
      Pittman et al 2007) prior to receiving their first test dose. These procedures will be
      done/overseen by research nurses or physicians. Subjects will usually receive their first
      intranasal test dose between 1000 and 1200 hours and will consist of 6 insufflations of
      Syntocinon Spray (approximately 24 IU) or placebo, with each insufflation given 30 seconds
      apart and alternating between nostrils. Test doses will be taken again at 1700 hr later that
      day (Admission Day 1) and at 0900 and 1700 hr on Admission Days 2 and 3. Oxytocin test
      treatments will be administered from 5 ml intranasal spray vials designed to deliver 0.1 ml
      metered volume per insufflation. The placebo treatments will be administered from 60 ml
      intranasal spray vials (each containing 30ml of solution) also designed to deliver 0.1ml
      metered volume per insufflation. Vials containing oxytocin and placebo spray will be blind
      labeled by the UNC Investigational Drug Service or the Dorothea Dix Hospital pharmacy.
      Research nurses or physicians will oversee subject self-administration of all intranasal test
      doses. After enrollment on admission day 1 and in the morning on admission days 2 and 3,
      subjects will be given multiple copies of the AWSC questionnaire and requested to complete
      one each time the unit nurses do CIWA ratings. These questionnaires will be retrieved by
      research staff the following morning. Shortly after the morning test dose on admission days 2
      and 3, subjects will complete the Alcohol Craving Visual Analog Scales (ACVAS), the Penn
      Alcohol Craving Scale, and the Profile of Mood States (McNair et al, 1971). On these same
      admission days, research nurses will also draw (and subsequently process) blood serum samples
      to assay cytokine and allopregnanolone concentrations shortly after the morning test dose.
      Additional blood will be drawn after the morning test dose on admission day 2 to obtain serum
      for tests to be run in McLendon Laboratories (magnesium, chloride, calcium, sodium,
      potassium, BUN, creatinine, and liver function tests). Another electrocardiogram (ECG) will
      also be obtained shortly after the morning test treatment on admission day 2. Research staff
      will retrieve on a daily basis CIWA ratings and vital sign measurements obtained on each
      subject from their electronic medical record.

      In all subjects, PRN lorazepam doses will be administered by mouth (PO) or intravenously (IV)
      (if subjects cannot take medication PO) whenever CIWA ratings are &gt; 14 per the protocol in
      the standard alcohol detoxification order set in the UNC Hospital CPOE system. Lorazepam
      doses (1 - 4 mg) and frequency (q 2 -6 h) will be adjusted based on the severity of
      withdrawal symptoms. This same order set will be employed at the Dorothea Dix CRU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Lorazepam Dosage (in Milligrams)</measure>
    <time_frame>Days 1 to 5</time_frame>
    <description>Total lorazepam (in milligrams) required per subject to complete detoxification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CIWA-Ar Scores</measure>
    <time_frame>days 1</time_frame>
    <description>Clinical Institute Withdrawal Assessment for Alcohol (CIWA) scale modified to include vital sign measurements. The CIWA scale measures each of 10 alcohol withdrawal symptoms between 0 and 6 (least to worst). Also in the modified CIWA score are ratings of body temperature (0-3, normal range to increasingly elevated), pulse (0-6), respirations (0-2), and diastolic blood pressure (0-6). So the range of possible total scores on the modified CIWA is 0-77.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>intranasal spray without oxytocin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily intranasal spray without oxytocin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intranasal oxytocin spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily intranasal oxytocin spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal oxytocin spray</intervention_name>
    <description>6 insufflations (24 IU of oxytocin total) given twice daily for 3 days</description>
    <arm_group_label>intranasal oxytocin spray</arm_group_label>
    <other_name>Syntocinon Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intranasal spray without oxytocin</intervention_name>
    <description>6 insufflations (0.1 metered dose/insufflation) twice daily</description>
    <arm_group_label>intranasal spray without oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Daily consumption of 6 or more alcohol drinks/day for at least 2 weeks prior to
             admission.

          -  Only one of the following two conditions must be met:

               1. At least one prior episode 2 days or longer in duration which the subject
                  experienced withdrawal symptoms that caused significant incapacitation.

               2. At least one prior inpatient or outpatient medical detoxification during which
                  the subject exhibited withdrawal symptoms that sedative-hypnotic or
                  anticonvulsant medication was required at least once on 2 consecutive days after
                  cessation of or reduction in the use of alcohol following 2 weeks or more of
                  heavily daily consumption (6 or more drinks/day).

        Exclusion Criteria:

          -  Low literacy as indicated by an inability to read and understand the consent form.

          -  Dependence on substances other than alcohol, nicotine, caffeine or cannabis.

          -  History of alcohol withdrawal-related seizures, delirium tremens or hallucinations.

          -  Current or past alcohol-related medical complications (e.g. cirrhosis of the liver,
             esophageal varices, severe gastritis, hemoptysis, hematochezia or melena).

          -  Current delirium, disorientation to place or persons, seizures, acute or unstable
             psychosis or mania.

          -  Suicidal or homicidal ideation with strong intent, plans or recent attempt.

          -  Debilitating medical conditions (including AIDS, seizure disorder, emphysema, cancer
             and not well-controlled diabetes/hypertension) [HIV infection, diabetes, hypertension
             and asthma will not be grounds for exclusion]

          -  Diagnosis of amnesia, dementia, cognitive impairment or significant neurological
             symptoms.

          -  Low body weight (BMI&lt;17).

          -  History of anorexia nervosa or bulimia in the past 2 years.

          -  Significant trauma, self injurious behavior or surgery in the previous 2 months

          -  Pregnancy; giving birth or breast-feeding in the past 6 months.

          -  Ingestion during the 2 weeks prior to this admission of much more alcohol/day than
             during previous drinking binges that preceded the onset of alcohol withdrawal
             symptoms.

          -  Ingestion of more than 450 ml of alcohol/day.

          -  Chronic treatment with benzodiazepines, barbiturates, anticonvulsants or stimulants

          -  Treatment/ingestion in the 72 hours prior to enrollment in the study with long
             half-life benzodiazepines or sedative hypnotic drugs.

          -  A blood alcohol level upon admission &gt; 300 mg/dl.

          -  Well-documented history of inadequately treated baseline hypertension or tachycardia
             (SBP&gt;150 or DBP&gt;100 or P&gt;110).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cort A Pedersen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of North Carolina, Chapel Hill, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Regional Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.psychiatry.unc.edu/</url>
    <description>UNC Department of Psychiatry</description>
  </link>
  <link>
    <url>http://www.psychiatry.unc.edu/research</url>
    <description>UNC Department of Psychiatry Research</description>
  </link>
  <link>
    <url>http://www.med.unc.edu/psych/psychoticdisorders/research/cru/CRU-DDH</url>
    <description>Clinical Research Unit at Central Regional Hospital</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <results_first_submitted>December 14, 2013</results_first_submitted>
  <results_first_submitted_qc>April 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2014</results_first_posted>
  <last_update_submitted>April 12, 2014</last_update_submitted>
  <last_update_submitted_qc>April 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Cort Pedersen, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>alcohol withdrawal</keyword>
  <keyword>lorazepam</keyword>
  <keyword>alcoholism</keyword>
  <keyword>intranasal administration</keyword>
  <keyword>CIWA-Ar</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Spray Without Oxytocin</title>
          <description>Twice daily intranasal spray without oxytocin.
intranasal spray without oxytocin: 6 insufflations (0.1 metered dose/insufflation) twice daily for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Intranasal Oxytocin Spray</title>
          <description>Twice daily intranasal oxytocin spray
intranasal oxytocin spray: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This was an intent to treat study in which data were collected and analyzed on all subjects in both treatment arms who were enrolled in the study and met eligibility criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Spray Without Oxytocin</title>
          <description>Twice daily intranasal spray without oxytocin.
intranasal spray without oxytocin: 6 insufflations (0.1 metered dose/insufflation) twice daily</description>
        </group>
        <group group_id="B2">
          <title>Intranasal Oxytocin Spray</title>
          <description>Twice daily intranasal oxytocin spray
intranasal oxytocin spray: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.09" spread="8.32"/>
                    <measurement group_id="B2" value="42.23" spread="10.87"/>
                    <measurement group_id="B3" value="41.27" spread="14.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CIWA-Ar score</title>
          <description>Clinical Institute Withdrawal Assessment for Alcohol (CIWA) scale modified to include vital sign measurements. The CIWA scale measures each of 10 alcohol withdrawal symptoms between 0 and 6 (least to worst). Also in the modified CIWA score are ratings of body temperature (0-3, normal range to increasingly elevated), pulse (0-6), respirations (0-2), and diastolic blood pressure (0-6). So the range of possible total scores on the modified CIWA is 0-77.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.25" spread="6.6"/>
                    <measurement group_id="B2" value="2.5" spread="1.4"/>
                    <measurement group_id="B3" value="4.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Standard drinks/day over the past 2 weeks</title>
          <description>A standard drink is defined as: 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces of 80-proof distilled spirits or liquor.</description>
          <units>standard drinks/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="1.7"/>
                    <measurement group_id="B2" value="17.7" spread="6.0"/>
                    <measurement group_id="B3" value="16.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Lorazepam Dosage (in Milligrams)</title>
        <description>Total lorazepam (in milligrams) required per subject to complete detoxification</description>
        <time_frame>Days 1 to 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Spray Without Oxytocin</title>
            <description>Twice daily intranasal spray without oxytocin.
intranasal spray without oxytocin: 6 insufflations (0.1 metered dose/insufflation) twice daily</description>
          </group>
          <group group_id="O2">
            <title>Intranasal Oxytocin Spray</title>
            <description>Twice daily intranasal oxytocin spray
intranasal oxytocin spray: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lorazepam Dosage (in Milligrams)</title>
          <description>Total lorazepam (in milligrams) required per subject to complete detoxification</description>
          <units>milligrams of lorazepam</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="4.4"/>
                    <measurement group_id="O2" value="3.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CIWA-Ar Scores</title>
        <description>Clinical Institute Withdrawal Assessment for Alcohol (CIWA) scale modified to include vital sign measurements. The CIWA scale measures each of 10 alcohol withdrawal symptoms between 0 and 6 (least to worst). Also in the modified CIWA score are ratings of body temperature (0-3, normal range to increasingly elevated), pulse (0-6), respirations (0-2), and diastolic blood pressure (0-6). So the range of possible total scores on the modified CIWA is 0-77.</description>
        <time_frame>days 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Spray Without Oxytocin</title>
            <description>Twice daily intranasal spray without oxytocin.
intranasal spray without oxytocin: 6 insufflations (0.1 metered dose/insufflation) twice daily</description>
          </group>
          <group group_id="O2">
            <title>Intranasal Oxytocin Spray</title>
            <description>Twice daily intranasal oxytocin spray
intranasal oxytocin spray: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>CIWA-Ar Scores</title>
          <description>Clinical Institute Withdrawal Assessment for Alcohol (CIWA) scale modified to include vital sign measurements. The CIWA scale measures each of 10 alcohol withdrawal symptoms between 0 and 6 (least to worst). Also in the modified CIWA score are ratings of body temperature (0-3, normal range to increasingly elevated), pulse (0-6), respirations (0-2), and diastolic blood pressure (0-6). So the range of possible total scores on the modified CIWA is 0-77.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="0.4"/>
                    <measurement group_id="O2" value="4.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Spray Without Oxytocin</title>
          <description>Twice daily intranasal spray without oxytocin.
intranasal spray without oxytocin: 6 insufflations (0.1 metered dose/insufflation) twice daily</description>
        </group>
        <group group_id="E2">
          <title>Intranasal Oxytocin Spray</title>
          <description>Twice daily intranasal oxytocin spray
intranasal oxytocin spray: 6 insufflations (24 IU of oxytocin total) given twice daily for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>electrolyte abnormalities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cort Pedersen</name_or_title>
      <organization>UNC_ChapelHill</organization>
      <phone>919-966-4447</phone>
      <email>cort_pedersen@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

